Scientific Founder & Chief Executive Officer
Dr. Borriello obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he studied Class I MHC structure-function relationships. He continued training at the Brigham and Women’s Hospital in Boston with a residency in clinical pathology and a laboratory research focus in cellular immunology and the B7-CD28 costimulatory pathway.
He has an extensive 20+ year background in the biotech/pharma industry spanning diverse roles such as clinical development (Wyeth), financial buy-side analyst (BB Biotech) and, most extensively, in the area of Business Development (Millennium, Takeda, Shire and Baxter) and, finally Baxalta, where he was VP of Search and Evaluation before its acquisition in 2016.
In 2016, he conceived a potentially differentiated, non-engineered approach to immuno-oncology (now ‘SUPLEXA’) and established Alloplex Biotherapeutics Inc.
Since then – as Scientific Founder and CEO of Alloplex – Dr. Borriello has led the organization through research, fundraising and business development, to Phase 1 clinical trials for SUPLEXA therapy which commenced recently in Australia.
SUPLEXA is a potential first-in-class, autologous, pan cancer-cellular therapy made from the patient’s own immune cells, and comprised primarily of cells with known anti-tumor killing cells such as NK cells, NKT cells and T cells.
Descending date order
Journal of Immunology 1997: 158 : 4548-4554.Borriello F, Lederer J, Scott S and AH Sharpe.
Immunity 1997: 6: 303-313.Borriello F, Sethna SP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ and AH Sharpe.
Immunol. 1995 Dec 15;155(12):5490-7.Borriello F, Oliveros J, Freeman GJ, Nadler LM, Sharpe AH.
Immunity 1995: 3: 541-547Tivol B, Borriello F, Schweitzer NA, Lynch WP, Bluestone JA and AH Sharpe.
Immunol. 1995 Jan;25(1):207-11.Prabhu Das MR, Zamvil SS, Borriello F, Weiner HL, Sharpe AH, Kuchroo VK.
Prabhu Das MR, Zamvil SS, Borriello F, Weiner HL, Sharpe AH, Kuchroo VK.Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, Gray GS, Nadler LM and AH Sharpe.
Journal of Experimental Medicine 1993: 178: 2185-2188.Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg J, Hathcock K, Laszlo G, Lombard L, Wang S, Gray GS, Nadler LM and AH Sharpe.
Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9417-21.Borriello F, Krauter KS.
Nucleic Acids Res. 1990 Sep 25;18(18):5481-7.Borriello F, Krauter KS.
Blood. 1991 Jul 15;78(2):524-32Zeff RA, Zhao YF, Tatake R, Lachman H, Borriello F, Nathenson SG.
Cell. 1988 Jul 1;54(1):47-56.Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG.
Biol Chem. 1988 Apr 5;263(10):4549-60.Williams DB, Borriello F, Zeff RA, Nathenson SG
Immunol Res. 1987;6(1-2):133-44.Zeff RA, Kumar PA, Mashimo H, Nakagawa M, McCue B, Borriello F, Kesari K, Geliebter J, Hemmi S, Pfaffenbach G, et al.